NK510

DRUG5 trials

Sponsors

Base Therapeutics (Shanghai) Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Solid TumorsColorectal CancerGastric CancerGastric Cancer (GC)Metastatic Solid TumorsNSCLCOsteosarcomaRare Malignant Neoplasm

Early Phase 1

Safety and Efficacy of NK510 to Treat NSCLC

RecruitingNCT06097962

Base Therapeutics (Shanghai) Co., Ltd.NSCLC

Start: 2023-07-01End: 2026-07-01Target: 12Updated: 2026-03-20

Safety and Efficacy of NK510 to Treat Gastric Cancer

Base Therapeutics (Shanghai) Co., Ltd.Gastric Cancer

Start: 2023-11-01End: 2024-11-01Target: 9Updated: 2023-10-25

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Base Therapeutics (Shanghai) Co., Ltd.Osteosarcoma, Soft Tissue Sarcoma

Start: 2022-09-01End: 2024-09-01Target: 12Updated: 2023-11-07

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Not yet recruitingNCT07166263

Base Therapeutics (Shanghai) Co., Ltd.Colorectal Cancer, Gastric Cancer (GC)

Start: 2025-11-30End: 2027-12-31Target: 15Updated: 2025-09-10

Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not yet recruitingNCT07307053

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Solid Tumors, Metastatic Solid Tumors, Rare Malignant Neoplasm

Start: 2026-01-01End: 2031-01-31Target: 600Updated: 2025-12-29